Recent advances in lowering CV risk with antidiabetic agents
Video navigation menu
- What can be done about the increasing prevalance of diabetes and associated CV disease? 0:15
- Assessing CV benefit of diabetes agents in large CV outcomes trials 2:41
- Targeting the SGLT2 transporter to lower blood glucose exerts various effects 3:24
- Are the EMPA-REG OUTCOMES results reproducible? 7:27
- Where are we now with anti-diabetic treatment in relation to lowering CV risk? 8:36
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.